リガンド・ファーマシューティカルズ【LGND】の掲示板

お疲れ様

>>14

“This deal represents an ‘OmniAb first’ in terms of enabling a venture investor to incubate a series of new companies with common OmniAb licensing terms, enabling their portfolio companies to focus on drug development and value creation from the start,” said John Higgins, Chief Executive Officer of Ligand. “The OmniAb business continues to expand, driven by industry demand for our leading antibody-discovery technology with multiple species and broad freedom-to-operate.”

Ligand Enters into Agreement with venBio to Make Worldwide OmniAb® Platform License Accessible to Portfolio Companies

March 30, 2018

SAN DIEGO-- Ligand Pharmaceuticals Inc., announces it has entered into an agreement with venBio Partners, a venture capital group focused on building and funding portfolio companies with potential first- and best-in-class therapeutic product applications, which permits venBio’s portfolio companies to enter into a pre-agreed worldwide OmniAb platform license agreement. Under any platform license agreement, venBio’s portfolio companies will be able to use the full OmniAb platform including OmniRat®, OmniMouse®, OmniFlic® and OmniChicken™ to discover fully human mono- and bispecific antibodies. Ligand is eligible to receive access payments, development and regulatory milestone payments, and tiered royalties for each product incorporating an OmniAb antibody. venBio’s future portfolio companies will be responsible for all costs related to the programs.

>>12

“This agreement provides Glenmark access to our transgenic animal technology platform that is the only to include three separate species in a single license. This diversity in species is expected to provide a wider repertoire of therapeutic antibodies than a single-species technology,” said John Higgins, Chief Executive Officer of Ligand. “This is the first new OmniAb partnership to include OmniChicken in addition to OmniRat, OmniMouse and OmniFlic. Ligand’s acquisition of OmniChicken demonstrated its commitment to provide the best antibody-discovery technologies to its current and future partners.”

てか、次はインドのグレンマークかいｗｗｗ
う～ん・・・
ちょっとなｗｗｗ

おおお、またライセンスアウトしたやんｗｗｗ

Ligand Enters into Worldwide OmniAb® Platform License Agreement with Glenmark Pharmaceuticals
January 11, 2018

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered a worldwide OmniAb platform license agreement with Glenmark Pharmaceuticals. Under the license, Glenmark will be able to use the full OmniAb platform including OmniChicken™, OmniRat®, OmniMouse® and OmniFlic® to discover fully human mono- and multispecific antibodies. Ligand is eligible to receive annual platform access payments, development and regulatory milestone payments and tiered royalties for each product incorporating an OmniAb antibody. Glenmark will be responsible for all costs related to the programs.

>>10

まあ韓国企業へのライセンスアウトなんで、、、

あんまり・・・？？？だなｗ
ｗｗｗ

>>9

Including these payments, Ligand now anticipates total revenue for full year 2017 to be approximately $140 million with adjusted EPS to be between $3.13 and $3.16. Previous guidance was for revenue to be between $134 and $136 million and for adjusted earnings per share to be between $2.95 and $3.00.

>>8

“These are excellent licensing transactions for HanAll and for Ligand, putting a clinical-stage antibody into the hands of two partners to advance the development of the program in markets around the world. The licenses illustrate the value and potential of the OmniAb platform for delivering novel antibodies that succeed through the intense discovery selection process,” said John Higgins, Chief Executive Officer of Ligand. “We are very pleased with HanAll's success in quickly moving one of its novel antibodies into human trials in 2017 and in subsequently securing two license agreements for the antibody. Ligand has a best-in-class antibody discovery technology with its OmniAb platform offering three distinct species for drug discovery. Since acquiring the technology less than two years ago, Ligand has expanded its portfolio of OmniAb partners and has secured substantial partnering payments as the programs advance.”

そして全ての哺乳動物、非哺乳動物抗体応用技術（小ネズミ、中ネズミ、ニワトリ）は、Ligand PharmaのOmniAB®プラットフォーム集約されるｗｗｗ

ttps://www.ligand.com/technologies/omniab
（ニワトリ担当用としてCrystal Biosciencesを買収）

>>5

“In less than two years, Ligand has assembled the world’s premier offerings of fully-human antibody discovery technologies based on number and variety of species, and the highest number of partners broadly deploying the platform. Antibody research is one of the largest areas of R&D investment by the pharma and biotech industries given the potential and medical impact for major new medicines. Ligand is now offering prospective partners a one-stop shop with its trademarked ‘Three Species, One-License’ OmniAb partnering opportunity. Ligand will continue to operate the highly-specialized and profitable Crystal research unit out of its current labs in Northern California.”

>>4

“Crystal Bio is an excellent, complementary addition to our OmniAb antibody discovery platform. The company adds a third species for fully-humanized antibody discovery for partners, four new fully-funded partnerships and projected growing annual revenue and positive cash flow to the business,” said John Higgins, Chief Executive Officer of Ligand Pharmaceuticals.

“Species diversification is very important in antibody discovery due to the expanding complexity of therapeutic targets being pursued by the industry, and given that not all species of animals will yield the same results,” he added.

>>3

Crystal’s license agreements will initially add four Shots on Goal to Ligand, bringing its fully-funded programs to more than 160. It is expected that the OmniChicken technology will be utilized by some of Ligand’s existing OmniAb partners and potential new partners. Crystal’s current licensees include Boehringer Ingelheim, Alexo Therapeutics, Achaogen, and an undisclosed large pharmaceutical company, most of which are pursuing multiple targets. This transaction also provides Ligand with an in-house antibody discovery laboratory to service OmniChicken R&D needs through contracted service.

Rob Etches, PhD, DSc, a Crystal co-founder and distinguished geneticist, is expected to join Ligand as Vice President, Antibody Technologies, further strengthening Ligand’s R&D leadership in the field of antibody research. Ligand will continue to operate the 19-person Crystal organization based in Emeryville, CA.

>>2

Gains complementary antibody technology and discovery lab, new revenue streams and four fully-funded partnerships with potential for milestones and royalties

Crystal is a leader in the difficult-to-address-epitope area of antibody research with its HuMab technology, which is believed to be the world’s only chicken-based human antibody platform to successfully generate human antibodies. As part of the OmniAb® brand, HuMab technology will be called OmniChicken™. Because of the evolutionary distance between birds and mammals, chickens enable the generation of novel antibodies against targets that are not immunogenic in mammals like mice and rats, the core species of Ligand’s existing OmniAb platform. The addition of the OmniChicken platform will be complementary to Ligand’s OmniAb technology, and further solidifies Ligand’s position as the world leader in novel, transgenic antibody discovery platforms.

ここが現在トリ抗体世界最強のCrystal Biosciencesを買収したとはビックリしたわｗ
もうトリ抗体応用は煮詰まって進捗が大分滞ってると思ってたからなｗ

それでも３０億弱の金額だからなｗ
LIV1205ADCの一本足打法のカイオムの時価総額は高すぎて異常ｗｗｗ

Ligand to Acquire Crystal Bioscience, the Leader in Chicken-derived Fully-human Antibody Generation, for $25 Million in Cash plus Additional Potential Payments

SAN DIEGO & EMERYVILLE, Calif.--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Crystal Bioscience, Inc. (Crystal) announce the signing of a merger agreement whereby Ligand will acquire Crystal, a leader in avian genetics and the generation of fully-human therapeutic antibodies. Under the terms of the agreement, Ligand will pay Crystal shareholders $25 million in cash at closing, up to an additional $10.5 million of success-based milestones, and revenue sharing from existing licensees for a defined period.

リガンド・ファーマシューティカルズについて話し合うスレッドです。
スレッドのテーマと無関係のコメント、もしくは他にふさわしいスレッドがあるコメントは削除されることがあります。

textreamのビジネス、株式、金融、投資、または証券に関するスレッドに参加する場合は、Yahoo! JAPAN利用規約を再読してください。

Yahoo! JAPANは情報の内容や正確さについて責任を負うことはできません。
その種の情報に基づいて行われた取引や投資決定に対しては、Yahoo! JAPANは何ら責任を負うものではありません。